Heart failure is strongly associated with obstructive and central sleep apnea. The landmark 2015 SERVE-HF trial showed that using adaptive servo-ventilation (ASV) for central sleep apnea (CSA) management was associated with an increased risk of all-cause and cardiovascular mortality among heart failure patients with reduced ejection fractions. Based on the result, the American Academy of Sleep Medicine and the European Society of Cardiology have recommended against the use of ASV for the treatment of CSA in patients with heart failure with an ejection fraction≤45%. Recently, the results from the ADVENT-HF trial have been formally published, indicating that ASV does not increase adverse outcomes and can improve patients' quality of life. Here, we go over these findings in detail.
Keyphrases
- sleep apnea
- ejection fraction
- heart failure
- positive airway pressure
- aortic stenosis
- acute heart failure
- obstructive sleep apnea
- phase iii
- study protocol
- phase ii
- clinical trial
- end stage renal disease
- left ventricular
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- atrial fibrillation
- open label
- cardiovascular events
- physical activity
- cardiac surgery
- cardiac resynchronization therapy
- cardiovascular disease
- intensive care unit
- depressive symptoms
- patient reported outcomes
- coronary artery disease
- acute kidney injury
- thoracic surgery
- aortic valve
- meta analyses